In our study, we showed that Dleu2-17aa treatment ameliorated EAE, a mouse model of multiple sclerosis, by reducing the numbers of inflammatory/effector CD4+ T cells and increasing the frequency of Treg cells in both the spleen and CNS of EAE mice. Here, DLEU2 is linked to multiple sclerosis.